Prostate cancer, BRCA-mutated
Revision as of 18:43, 2 May 2021 by Jwarner (talk | contribs) (→Regimen {{#subobject:68aa39|Variant=1}})
Page editor | Section editor | ||
---|---|---|---|
Laura S. Graham, MD University of Washington Fred Hutchinson Cancer Research Center Seattle, WA LauraGrahamMD |
Ali Raza Khaki, MD Stanford University Palo Alto, CA arkhaki |
7 regimens on this page
8 variants on this page
|
Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the main prostate cancer page for other regimens.
Metastatic castration-resistant
Rucaparib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
(TRITON2) | 2017-NR | Phase II (RT) |
Note: this study is the basis of FDA approval; however, no dosing details are provided on CT.gov and there are no published manuscripts to date.
Targeted therapy
References
- TRITON2: NCT02952534